B-Myc Inhibitors

Chemical inhibitors of B-Myc can interfere with the protein's function through various mechanisms. 10058-F4 and 10074-G5 directly target the dimerization domain of Myc proteins, a process crucial for their activity as transcription factors. By inhibiting dimerization, these chemicals impair B-Myc's ability to form heterodimers with Max, which is essential for its binding to E-box DNA sequences and subsequent transcriptional activation of target genes. JQ1 and KJ-Pyr-9 inhibit the BET family of bromodomains, such as BRD4, which are known to regulate gene expression by modifying chromatin structure. This inhibition can reduce the chromatin-binding capability of B-Myc, thus restricting its transcriptional activity.

Further, Thalidomide promotes the degradation of transcription factors through recruitment of the E3 ubiquitin ligase cereblon, leading to the proteasomal degradation of B-Myc. I-BET151, like JQ1, targets BET bromodomains, potentially limiting B-Myc's recruitment to chromatin and thereby its transcriptional activity. SGC-CBP30 hampers the activity of acetyltransferases CBP/p300, which can alter the acetylation status of B-Myc, affecting its stability and transcriptional coactivation process. YK-4-279 disrupts the interaction of ETS transcription factors with their target DNA sequences, which could also impair the ETS-related transcriptional activities of B-Myc. C646, by inhibiting the acetyltransferase activity of p300/CBP, may reduce the acetylation-mediated activation of B-Myc, impacting its function. EPZ-5676 and GSK126 inhibit enzymes responsible for methylating histones (DOT1L and EZH2, respectively), which can change chromatin states and indirectly limit the ability of B-Myc to regulate gene expression, affecting its role in cell proliferation and growth.